GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark becomes the First Pharmaceutical Company to launch Teneligliptin + Pioglitazone Fixed-Dose Combination Drug for Type 2 Diabetes in India Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
Net Sales are expected to increase by 5.1 percent Y-o-Y (down 5.3 percent Q-o-Q) to Rs 3,006.1 crore, according to Prabhudas Lilladher. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Postal Ballot Notice GLENMARK PHARMACEUTICALS LTD. - 532296 - Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2022
Certificate from Practicing Company Secretary under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Financial year ended 31st March, 2022 GLENMARK PHARMACEUTICALS LTD. - 532296 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Intimation regarding Notice of Postal Ballot - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 GLENMARK PHARMACEUTICALS LTD. - 532296 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Harish KuberDesignation :- Company Secretary and Compliance Officer
Glenmark to conduct clinical trials of its molecule on cancer patients
Glenmark Pharmaceuticals on Monday said its unit has received approval from the DCGI to conduct phase 1 clinical trials of its novel molecule on patients with advanced solid tumors. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin's Lymphoma GLENMARK PHARMACEUTICALS LTD. - 532296 - Notice Of Early Redemption By Glenmark Pharmaceuticals Limited (The "Company") To The Holders Of Its U.S.$200,000,000 2.00 Per Cent. Resettable Onward Starting Equity-Linked Securities Due 2022 ("Bonds")
Notice of Early Redemption by Glenmark Pharmaceuticals Limited (the "Company") to the holders of its U.S.$200,000,000 2.00 per cent. Resettable Onward Starting Equity-linked Securities Due 2022 ("Bonds"). GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Of Buyback By Glenmark Pharmaceuticals Limited (The "Company") In Respect Of The US$ 200,000,000 2.00% Resettable Onward Starting Equity-Linked Securities Due 2022 (The 'FCC Bonds')
Intimation of buyback by Glenmark Pharmaceuticals Limited (the "Company") in respect of the US$ 200,000,000 2.00% Resettable Onward Starting Equity-Linked Securities due 2022 (the 'FCC Bonds')